Is sandostatin used for carcinoid syndrome?

Is Sandostatin used for carcinoid syndrome?

Sandostatin (octreotide) is approved to control the flushing and diarrhea that define carcinoid syndrome. It works by binding somatostatin receptors on tumor cells, slowing hormone release and easing symptoms in most patients.

What dose is typically given for carcinoid syndrome?

The usual starting regimen is 100–600 mcg daily by subcutaneous injection, divided into two or three doses. Long-acting Sandostatin LAR is started at 20 mg intramuscularly every four weeks once symptoms are stable.

How quickly does Sandostatin relieve symptoms?

Many patients notice fewer bowel movements and less flushing within days of the first injections. Full control often takes one to two weeks as dosing is adjusted.

Why do some patients still have breakthrough symptoms?

Tumor progression, receptor down-regulation, or inadequate dosing can allow symptoms to return. Doctors may raise the dose, shorten the injection interval, or add other agents such as telotristat ethyl.

Can Sandostatin shrink carcinoid tumors?

The drug mainly reduces hormone output rather than shrinking tumors. Modest tumor stabilization is seen in some patients, but objective shrinkage is uncommon.

When does Sandostatin patent protection end?

U.S. market exclusivity for the long-acting formulation expired years ago, and several generic octreotide products are now available. [1]

What alternatives exist if Sandostatin stops working?

Physicians may switch to lanreotide (Somatuline Depot), pasireotide, or add peptide-receptor radionuclide therapy for refractory cases.

How much does treatment cost without insurance?

Cash prices for generic octreotide range from roughly $50–150 per month for the short-acting form and $3,000–5,000 per dose for the long-acting form, though actual out-of-pocket costs vary by plan and pharmacy. DrugPatentWatch.com tracks current patent and pricing data.